Skip to content
Parakho

Natco Pharma Ltd

NSE NATCOPHARMBSE 524816natcopharma.co.in

Q1 FY27, unaudited

Revenue
₹596.60 Cr
Profit after tax
₹74.60 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations596.60−49.98%3,594.60
Other income48.30−18.96%281.10
Total income644.90−48.50%3,875.70
Employee benefit expense151.40+5.51%591.70
Finance costs9.60+269.23%32.30
Depreciation & amortisation42.70−20.63%189.60
Total expenses542.90−23.47%2,511.60
Profit before tax102.00−81.21%1,364.10
Tax expense27.40−65.23%82.60
Profit after tax74.60−83.93%1,281.50
Total comprehensive income85.30−81.77%1,308.30
Earnings per share
Earnings per share, basic₹4.17₹71.55
Earnings per share, diluted₹4.17₹71.55

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

Q1 FY26, the year-ago base — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Earnings call

Q4 FY26

NATCO Pharma reported consolidated revenue of Rs 4,375.9 crores for FY26 versus Rs 4,784 crores last year, with net profit of Rs 1,418.5 crores against Rs 1,883.4 crores, as lenalidomide-related exclusivity revenue declined. Management guided to a decline in FY27 earnings to a base level of Rs 700-750 crores PAT on revenue of Rs 3,400-3,500 crores, citing the absence of major exclusivities in the coming year. The company discussed its semaglutide launch, South African associate Adcock Ingram, ongoing search for acquisitions, and plans to demerge its Crop Health Sciences business.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 36 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.